SE9400088D0
(sv)
*
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
US6740734B1
(en)
|
1994-01-14 |
2004-05-25 |
Biovitrum Ab |
Bacterial receptor structures
|
KR100249442B1
(ko)
*
|
1995-12-27 |
2000-05-01 |
시바타 마사하루 |
스트렙토코커스아갈락티아에ia형또는ib형표면다당을주성분으로하는암전이저해제
|
GB9722131D0
(en)
*
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
SE9704141D0
(sv)
*
|
1997-11-12 |
1997-11-12 |
Sbl Vaccin Ab |
New protein and nucleotide sequence, encoding said protein
|
GB9823071D0
(en)
*
|
1998-10-21 |
1998-12-16 |
Affibody Technology Ab |
A method
|
SE9901379D0
(sv)
|
1999-04-19 |
1999-04-19 |
Pharmacia & Upjohn Ab |
Receptor structures
|
US6602977B1
(en)
|
1999-04-19 |
2003-08-05 |
Biovitrum Ab |
Receptor structures
|
CA2374013A1
(en)
*
|
1999-05-15 |
2000-11-23 |
University Of California, San Diego |
Protein a based binding domains with desirable activities
|
US7163686B1
(en)
|
1999-05-15 |
2007-01-16 |
The Regents Of The University Of California |
Protein A based binding domains with desirable activities
|
GB9917027D0
(en)
*
|
1999-07-20 |
1999-09-22 |
Affibody Technology Sweeden Ab |
In vitro selection and optional identification of polypeptides using solid support carriers
|
ATE422369T1
(de)
*
|
1999-12-24 |
2009-02-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
|
GB0017720D0
(en)
*
|
2000-07-19 |
2000-09-06 |
Got A Gene Ab |
Modified virus
|
WO2002056024A2
(en)
*
|
2001-01-12 |
2002-07-18 |
Affibody Ab |
Detection methods
|
US20040077017A1
(en)
*
|
2001-01-12 |
2004-04-22 |
Amelie Karlstrom |
Detection methods
|
DK1390535T3
(da)
*
|
2001-04-26 |
2010-12-06 |
Amgen Mountain View Inc |
Kombinatoriske biblioteker af monomer-domæner
|
US20050053973A1
(en)
*
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20050048512A1
(en)
*
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20030157561A1
(en)
*
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
US20040175756A1
(en)
*
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
FI115343B
(fi)
*
|
2001-10-22 |
2005-04-15 |
Filtronic Lk Oy |
Sisäinen monikaista-antenni
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
US20040009530A1
(en)
*
|
2002-01-16 |
2004-01-15 |
Wilson David S. |
Engineered binding proteins
|
SE0200943D0
(sv)
*
|
2002-03-25 |
2002-03-25 |
Amersham Biosciences Ab |
Mutant protein
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
EP1517921B1
(de)
*
|
2002-06-28 |
2006-06-07 |
Domantis Limited |
Dual-specifische liganden mit erhöhter halbwertszeit
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
US20050074865A1
(en)
|
2002-08-27 |
2005-04-07 |
Compound Therapeutics, Inc. |
Adzymes and uses thereof
|
EP1599597B1
(de)
*
|
2003-02-24 |
2010-08-04 |
Pritest, Inc. |
Lichtdurchlässige festmatrix-prüfvorrichtung zur mikroarray-analyse
|
US6861251B2
(en)
|
2003-02-24 |
2005-03-01 |
Pritest, Inc. |
Translucent solid matrix assay device for microarray analysis
|
US20060177870A1
(en)
*
|
2003-04-28 |
2006-08-10 |
Ciphergen Biosystems, Inc |
Immunoassays
|
PT2382990E
(pt)
|
2003-04-30 |
2014-12-29 |
Univ Zuerich |
Método para tratamento do cancro usando uma imunotoxina
|
AU2004253835B2
(en)
*
|
2003-07-04 |
2009-01-29 |
Affibody Ab |
Polypeptides having binding affinity for HER2
|
US7956165B2
(en)
|
2003-07-24 |
2011-06-07 |
Affisink Biotechnology Ltd. |
Compositions and methods for purifying and crystallizing molecules of interest
|
IL157086A0
(en)
*
|
2003-07-24 |
2004-02-08 |
Guy Patchornik |
Multivalent ligand complexes
|
US20050181398A1
(en)
*
|
2004-01-16 |
2005-08-18 |
Fung Eric T. |
Specific detection of host response protein clusters
|
JP5634008B2
(ja)
|
2004-04-06 |
2014-12-03 |
アフィボディ・アーベー |
新規の使用および方法
|
US8092549B2
(en)
|
2004-09-24 |
2012-01-10 |
The Invention Science Fund I, Llc |
Ciliated stent-like-system
|
US8361013B2
(en)
|
2004-04-19 |
2013-01-29 |
The Invention Science Fund I, Llc |
Telescoping perfusion management system
|
US9011329B2
(en)
|
2004-04-19 |
2015-04-21 |
Searete Llc |
Lumenally-active device
|
US8512219B2
(en)
|
2004-04-19 |
2013-08-20 |
The Invention Science Fund I, Llc |
Bioelectromagnetic interface system
|
US7857767B2
(en)
|
2004-04-19 |
2010-12-28 |
Invention Science Fund I, Llc |
Lumen-traveling device
|
US7998060B2
(en)
|
2004-04-19 |
2011-08-16 |
The Invention Science Fund I, Llc |
Lumen-traveling delivery device
|
US8353896B2
(en)
|
2004-04-19 |
2013-01-15 |
The Invention Science Fund I, Llc |
Controllable release nasal system
|
US7850676B2
(en)
|
2004-04-19 |
2010-12-14 |
The Invention Science Fund I, Llc |
System with a reservoir for perfusion management
|
US8337482B2
(en)
|
2004-04-19 |
2012-12-25 |
The Invention Science Fund I, Llc |
System for perfusion management
|
US8019413B2
(en)
|
2007-03-19 |
2011-09-13 |
The Invention Science Fund I, Llc |
Lumen-traveling biological interface device and method of use
|
BRPI0511755A
(pt)
*
|
2004-06-01 |
2008-01-02 |
Domantis Ltd |
composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
|
CA2486285C
(en)
*
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
US7563443B2
(en)
*
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
KR20070084069A
(ko)
|
2004-10-08 |
2007-08-24 |
도만티스 리미티드 |
Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법
|
BRPI0518761A2
(pt)
|
2004-12-02 |
2008-12-09 |
Domantis Ltd |
fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
|
EP1846444A2
(de)
*
|
2004-12-22 |
2007-10-24 |
Lipopeptide AB |
Das cathelinähnliche protein cap18/ll-37 hemmende mittel
|
US20070003528A1
(en)
|
2005-06-29 |
2007-01-04 |
Paul Consigny |
Intracoronary device and method of use thereof
|
NZ568762A
(en)
|
2005-11-07 |
2011-11-25 |
Scripps Research Inst |
Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
|
GB0524788D0
(en)
*
|
2005-12-05 |
2006-01-11 |
Affibody Ab |
Polypeptides
|
US20110172826A1
(en)
*
|
2005-12-14 |
2011-07-14 |
Amodei Dario G |
Device including altered microorganisms, and methods and systems of use
|
US20110184387A1
(en)
*
|
2010-01-22 |
2011-07-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Compositions and methods for therapeutic delivery with microorganisms
|
US8278094B2
(en)
|
2005-12-14 |
2012-10-02 |
The Invention Science Fund I, Llc |
Bone semi-permeable device
|
US8734823B2
(en)
|
2005-12-14 |
2014-05-27 |
The Invention Science Fund I, Llc |
Device including altered microorganisms, and methods and systems of use
|
US8682619B2
(en)
|
2005-12-14 |
2014-03-25 |
The Invention Science Fund I, Llc |
Device including altered microorganisms, and methods and systems of use
|
US20090053790A1
(en)
|
2006-01-31 |
2009-02-26 |
Ishihara Sangyo Kaisha, Ltd. |
Polypeptide Having Affinity for Envelope Virus Constituent and Use Thereof in Transferring Substance Into Cell
|
US20120035437A1
(en)
|
2006-04-12 |
2012-02-09 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Navigation of a lumen traveling device toward a target
|
US8160680B2
(en)
|
2006-04-12 |
2012-04-17 |
The Invention Science Fund I, Llc |
Autofluorescent imaging and target ablation
|
WO2007139397A1
(en)
*
|
2006-05-26 |
2007-12-06 |
Waikatolink Limited |
Ob fold domains
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
MX2009002418A
(es)
|
2006-09-05 |
2009-04-23 |
Medarex Inc |
Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
|
PT2066351E
(pt)
|
2006-10-02 |
2015-11-30 |
Squibb & Sons Llc |
Anticorpos humanos que se ligam a cxcr4 e utilizações dos mesmos
|
US20080096233A1
(en)
*
|
2006-10-20 |
2008-04-24 |
Robotti Karla M |
Isolation Of Immune Complexes
|
GB0621513D0
(en)
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
CA2671457C
(en)
|
2006-12-01 |
2017-09-26 |
Medarex, Inc. |
Human antibodies that bind cd22 and uses thereof
|
US8198043B2
(en)
*
|
2006-12-08 |
2012-06-12 |
General Electric Company |
Two helix binders
|
US7981691B2
(en)
*
|
2006-12-08 |
2011-07-19 |
General Electric Company |
Two helix binders
|
US7989216B2
(en)
*
|
2006-12-08 |
2011-08-02 |
General Electric Company |
Two helix binders
|
US7977118B2
(en)
*
|
2006-12-08 |
2011-07-12 |
General Electric Company |
Two helix binders
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
KR20090088946A
(ko)
|
2006-12-14 |
2009-08-20 |
메다렉스, 인코포레이티드 |
씨디70에 결합하는 인간 항체 및 이의 용도
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP2121745A2
(de)
|
2007-02-26 |
2009-11-25 |
Oxford Genome Sciences (UK) Limited |
Proteine
|
US8303960B2
(en)
*
|
2007-02-27 |
2012-11-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Radiolabeled affibody molecules
|
WO2008124632A1
(en)
*
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Amphiphilic compound assisted nanoparticles for targeted delivery
|
GB0708376D0
(en)
|
2007-05-01 |
2007-06-06 |
Alligator Bioscience Ab |
Novel polypeptides and uses thereof
|
MX2009013269A
(es)
|
2007-06-05 |
2010-04-21 |
Univ Yale |
Inhibidores de receptor de cinasas de tirosina y metodos de uso de los mismos.
|
SG149759A1
(en)
|
2007-07-10 |
2009-02-27 |
Millipore Corp |
Media for affinity chromatography
|
EP2183275B1
(de)
|
2007-08-03 |
2014-10-29 |
Affibody AB |
Igf-1r bindende peptide und deren verwendung
|
EP2192922A4
(de)
|
2007-09-17 |
2010-09-29 |
Univ California |
Auf prostatazellen in situ abzielende internalisierende humane monoklonale antikörper
|
MX2010003099A
(es)
|
2007-09-21 |
2010-05-17 |
Univ California |
Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素(sclerostin)抗體組合物及使用方法
|
GB2453589A
(en)
|
2007-10-12 |
2009-04-15 |
King S College London |
Protease inhibition
|
EP3536336A1
(de)
|
2007-11-30 |
2019-09-11 |
Siemens Healthcare Diagnostics Inc. |
Adiponectin-rezeptor-agonisten und verfahren zur verwendung
|
EP2077272A1
(de)
*
|
2007-12-21 |
2009-07-08 |
Affibody AB |
Polypeptid-Bibliothek mit vorbestimmtem Gerüst
|
US9187535B2
(en)
|
2007-12-19 |
2015-11-17 |
Affibody Ab |
Polypeptide derived from protein A and able to bind PDGF
|
EP2072525A1
(de)
|
2007-12-21 |
2009-06-24 |
Affibody AB |
Neue Polypeptide mit Bindungsaffinität für HER2
|
WO2009080829A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Agents targeting cd138 and uses thereof
|
AR069980A1
(es)
*
|
2007-12-26 |
2010-03-03 |
Biotest Ag |
Inmunoconjugados dirigidos contra cd 138 y sus usos
|
WO2009080832A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Methods and agents for improving targeting of cd138 expressing tumor cells
|
EP2238169A1
(de)
*
|
2007-12-26 |
2010-10-13 |
Biotest AG |
Verfahren zur verminderung der zytotoxischen nebenwirkungen und zur erhöhung der wirksamkeit von immunkonjugaten
|
WO2009146099A2
(en)
|
2008-04-02 |
2009-12-03 |
Georgia State University Research Foundation, Inc. |
Contrast agents, methods for preparing contrast agents, and methods of imaging
|
EP2700651B1
(de)
|
2008-07-18 |
2019-04-10 |
Bristol-Myers Squibb Company |
Zur Bindung von CD28 monovalente Zusammensetzungen und Verfahren zur Verwendung
|
US20100022497A1
(en)
*
|
2008-07-24 |
2010-01-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
|
US20100022494A1
(en)
*
|
2008-07-24 |
2010-01-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
|
US20100061976A1
(en)
*
|
2008-07-24 |
2010-03-11 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
|
US20100022991A1
(en)
*
|
2008-07-24 |
2010-01-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and device for maintaining physiological levels of steroid hormone in a subject
|
KR20110036638A
(ko)
|
2008-07-25 |
2011-04-07 |
리차드 더블유. 와그너 |
단백질 스크리닝 방법
|
MX356218B
(es)
|
2008-08-05 |
2018-05-18 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
|
US8592555B2
(en)
|
2008-08-11 |
2013-11-26 |
Emd Millipore Corporation |
Immunoglobulin-binding proteins with improved specificity
|
US9187330B2
(en)
|
2008-09-15 |
2015-11-17 |
The Invention Science Fund I, Llc |
Tubular nanostructure targeted to cell membrane
|
US20100137246A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-inflammatory compositions and methods
|
US20100137844A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Delivery devices for modulating inflammation
|
US20100136095A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems for modulating inflammation
|
US20100136094A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems for modulating inflammation
|
US20100136097A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems for modulating inflammation
|
US20100135983A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-inflammatory compositions and methods
|
US20100136096A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems for modulating inflammation
|
US20120041286A1
(en)
|
2008-12-04 |
2012-02-16 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems, devices, and methods including implantable devices with anti-microbial properties
|
JP5985826B2
(ja)
|
2008-12-16 |
2016-09-06 |
ノバルティス アーゲー |
酵母ディスプレイ系
|
US20120165650A1
(en)
|
2010-12-22 |
2012-06-28 |
General Electric Company |
Her2 binders
|
SG162687A1
(en)
|
2008-12-24 |
2010-07-29 |
Millipore Corp |
Caustic stable chromatography ligands
|
WO2010084408A2
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
US8167871B2
(en)
|
2009-02-25 |
2012-05-01 |
The Invention Science Fund I, Llc |
Device for actively removing a target cell from blood or lymph of a vertebrate subject
|
US8721618B2
(en)
|
2009-02-25 |
2014-05-13 |
The Invention Science Fund I, Llc |
Device for actively removing a target cell from blood or lymph of a vertebrate subject
|
US8430831B2
(en)
*
|
2009-02-25 |
2013-04-30 |
The Invention Science Fund I, Llc |
Device, system, and method for controllably reducing inflammatory mediators in a subject
|
US8317737B2
(en)
*
|
2009-02-25 |
2012-11-27 |
The Invention Science Fund I, Llc |
Device for actively removing a target component from blood or lymph of a vertebrate subject
|
KR101769160B1
(ko)
|
2009-03-05 |
2017-08-17 |
옥스포드 바이오테라퓨틱스 리미티드 |
Cadm1에 특이적인 완전 인간 항체
|
GB0904355D0
(en)
|
2009-03-13 |
2009-04-29 |
Imp Innovations Ltd |
Biological materials and uses thereof
|
US9834815B2
(en)
|
2009-03-25 |
2017-12-05 |
Life Technologies Corporation |
Discriminatory positive/extraction control DNA
|
US8728479B2
(en)
|
2009-03-31 |
2014-05-20 |
The Trustees Of The University Of Pennsylvania |
Antigen-binding proteins comprising recombinant protein scaffolds
|
WO2010112193A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
US9181339B2
(en)
|
2009-04-20 |
2015-11-10 |
Oxford Bio Therapeutics Ltd. |
Antibodies specific to cadherin-17
|
EP2422199B1
(de)
|
2009-04-23 |
2018-07-25 |
Siemens Healthcare Diagnostics Inc. |
Monomere und dimere formen von adiponectin-rezeptorfragmenten sowie verwendungsverfahren dafür
|
PT2424895T
(pt)
|
2009-04-27 |
2017-12-15 |
Novartis Ag |
Composições e métodos para aumentar o crescimento muscular
|
MX2011011338A
(es)
|
2009-04-27 |
2012-04-19 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
|
US8154285B1
(en)
|
2009-05-29 |
2012-04-10 |
The Invention Science Fund I, Llc |
Non-external static magnetic field imaging systems, devices, methods, and compositions
|
US8106655B2
(en)
*
|
2009-05-29 |
2012-01-31 |
The Invention Science Fund I, Llc |
Multiplex imaging systems, devices, methods, and compositions including ferromagnetic structures
|
US8058872B2
(en)
|
2009-05-29 |
2011-11-15 |
The Invention Science Fund I, Llc |
Systems, devices, methods, and compositions including functionalized ferromagnetic structures
|
US20100303733A1
(en)
*
|
2009-05-29 |
2010-12-02 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Systems, devices, methods, and compositions including ferromagnetic structures
|
US8063636B2
(en)
*
|
2009-05-29 |
2011-11-22 |
The Invention Science Fund I, Llc |
Systems, devices, methods, and compositions including targeted ferromagnetic structures
|
IE20090514A1
(en)
|
2009-07-06 |
2011-02-16 |
Opsona Therapeutics Ltd |
Humanised antibodies and uses therof
|
DK2464657T3
(en)
|
2009-08-10 |
2015-06-29 |
Morphosys Ag |
New screening strategies for the identification of antibodies or fragments thereof which bind an antigen with enzymatic activity
|
US9024766B2
(en)
*
|
2009-08-28 |
2015-05-05 |
The Invention Science Fund, Llc |
Beverage containers with detection capability
|
US8810417B2
(en)
*
|
2009-08-28 |
2014-08-19 |
The Invention Science Fund I, Llc |
Beverage immersate with detection capability
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
NZ598962A
(en)
|
2009-09-16 |
2014-12-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
JP5954876B2
(ja)
|
2009-10-13 |
2016-07-20 |
ナノストリング テクノロジーズ, インコーポレイテッド |
ナノレポーターによるタンパク質の検出
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
US20120282276A1
(en)
|
2009-11-05 |
2012-11-08 |
The Regents Of The University Of Michigan |
Biomarkers predictive of progression of fibrosis
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
WO2011074717A1
(ko)
*
|
2009-12-15 |
2011-06-23 |
Choe Muhyeon |
단량체에 접착특이성이 있는 접착체의 반복사슬과 다수단량체의 복합체 내에서의 결합 가교의 생성 증가를 통한 이량체 및 다량체의 생산방법
|
JP2013519869A
(ja)
|
2010-02-10 |
2013-05-30 |
ノバルティス アーゲー |
筋肉成長のための方法および化合物
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
KR101860963B1
(ko)
|
2010-04-23 |
2018-05-24 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
MX2012012927A
(es)
|
2010-05-06 |
2013-05-01 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
|
EA201291180A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
CN110437320B
(zh)
|
2010-07-09 |
2023-10-20 |
阿菲博迪公司 |
多肽
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
JP2013537539A
(ja)
|
2010-08-13 |
2013-10-03 |
ジェネンテック, インコーポレイテッド |
疾患の治療のためのIL−1β及びIL−18に対する抗体
|
KR102027011B1
(ko)
|
2010-08-20 |
2019-09-30 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
KR101586128B1
(ko)
|
2010-08-24 |
2016-01-15 |
에프. 호프만-라 로슈 아게 |
디술피드 안정화 ― Fv 단편을 포함하는 이중특이적 항체
|
ES2678145T3
(es)
|
2010-08-24 |
2018-08-09 |
Abbott Laboratories |
Anticuerpos específicos contra la proteína del núcleo del VIH y usos de los mismos
|
SG188666A1
(en)
|
2010-09-30 |
2013-05-31 |
Agency Science Tech & Res |
Methods and reagents for detection and treatment of esophageal metaplasia
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−il12rベータ1抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
EP2655404B1
(de)
|
2010-12-21 |
2017-11-15 |
The University of Western Ontario |
Neue alkalibeständige varianten von protein a und ihre verwendung in der affinitätschromatography
|
WO2012086660A1
(ja)
|
2010-12-21 |
2012-06-28 |
Jsr株式会社 |
アフィニティークロマトグラフィー用担体およびイムノグロブリンを単離する方法
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
EP2670863B1
(de)
|
2011-01-31 |
2018-06-27 |
H. Hoffnabb-La Roche Ag |
Verfahren zur identifizierung mehrerer epitope in zellen
|
MX355255B
(es)
|
2011-02-04 |
2018-04-11 |
Genentech Inc |
Variantes de fc y métodos para su producción.
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
EP2673297A2
(de)
|
2011-02-11 |
2013-12-18 |
Zyngenia, Inc. |
Monovalente und multivalente multispezifische komplexe und verwendungen davon
|
GB201114858D0
(en)
|
2011-08-29 |
2011-10-12 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies and methods of using the same
|
SG194793A1
(en)
|
2011-05-06 |
2013-12-30 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies and methods of preparing and using the same
|
PT3498732T
(pt)
|
2011-05-06 |
2022-02-02 |
Zoetis Services Llc |
Anticorpos anti-fator de crescimento do nervo e método para preparação e utilização dos mesmos
|
CA2834983C
(en)
|
2011-05-06 |
2020-11-17 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies and methods of preparing and using the same
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
SG10201604559TA
(en)
|
2011-06-08 |
2016-07-28 |
Emd Millipore Corp |
Chromatography matrices including novel staphylococcus aureus protein a based ligands
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
US9447178B2
(en)
|
2011-06-28 |
2016-09-20 |
Oxford Biotherapeutics Ltd. |
Therapeutic and diagnostic target
|
SG10201605323SA
(en)
|
2011-06-28 |
2016-08-30 |
Oxford Biotherapeutics Ltd |
Antibodies to adp-ribosyl cyclase 2
|
PT2726099T
(pt)
|
2011-07-01 |
2018-11-13 |
Novartis Ag |
Método para o tratamento de distúrbios metabólicos
|
US9238689B2
(en)
|
2011-07-15 |
2016-01-19 |
Morpho Sys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
|
US9701749B2
(en)
|
2011-08-11 |
2017-07-11 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising PD-1 agonist
|
PL3418306T3
(pl)
|
2011-10-11 |
2024-04-15 |
F. Hoffmann-La Roche Ag |
Ulepszone składanie przeciwciał dwuswoistych
|
CN109111523B
(zh)
|
2011-10-14 |
2022-06-07 |
诺华股份有限公司 |
用于Wnt途径相关疾病的抗体和方法
|
WO2013077573A1
(ko)
|
2011-11-25 |
2013-05-30 |
서울대학교산학협력단 |
B형 간염 바이러스 유래 cis-작용 조절 엘리먼트 및 그 용도
|
BR112014013568A8
(pt)
|
2011-12-05 |
2017-06-13 |
Novartis Ag |
anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
|
EP3590538A1
(de)
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antikörper für den epidermalen wachstumsfaktorrezeptor 3 (her 3)
|
JP6218746B2
(ja)
|
2011-12-08 |
2017-10-25 |
バイオテスト・アクチエンゲゼルシヤフト |
Cd138を標的とする免疫複合体の使用
|
PE20150159A1
(es)
|
2011-12-21 |
2015-02-08 |
Novartis Ag |
Composiciones y metodos para anticuerpos que actuan sobre el factor p
|
CN104105711B
(zh)
|
2012-02-10 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
单链抗体及其他异多聚体
|
SI2817329T1
(sl)
|
2012-02-20 |
2019-04-30 |
Swedish Orphan Biovitrum Ab (Publ) |
Polipeptidi, ki se vežejo na človeški komplement c5
|
CA2865243A1
(en)
|
2012-02-23 |
2013-08-29 |
President And Fellows Of Harvard College |
Modified microbial toxin receptor for delivering agents into cells
|
KR20210075191A
(ko)
|
2012-03-28 |
2021-06-22 |
애피바디 에이비 |
경구투여
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
KR20150023889A
(ko)
|
2012-06-27 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
|
WO2014013016A1
(en)
|
2012-07-20 |
2014-01-23 |
Affibody Ab |
Method for determining the her2 status of a malignancy
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
JP6525872B2
(ja)
|
2012-08-08 |
2019-06-05 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
細胞中の複数のエピトープを同定するためのダイナミックレンジを高めること
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CN111763247A
(zh)
|
2012-09-25 |
2020-10-13 |
阿菲博迪公司 |
白蛋白结合多肽
|
WO2014076179A1
(en)
|
2012-11-14 |
2014-05-22 |
Affibody Ab |
New polypeptide
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
PL2928921T3
(pl)
|
2012-12-05 |
2021-06-28 |
Novartis Ag |
Kompozycje i sposoby dla przeciwciał celujących w epo
|
EP2931293B1
(de)
|
2012-12-12 |
2019-02-20 |
University Of Virginia Patent Foundation |
Zusammensetzungen und verfahren zur regulierung der erythropoiese
|
US9897611B2
(en)
|
2012-12-27 |
2018-02-20 |
National Institute Of Advanced Industrial Science And Technology |
Molecule library constructed on the basis of backbone structure of microprotein
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
ES2758473T3
(es)
|
2013-02-08 |
2020-05-05 |
Novartis Ag |
Anticuerpos anti-IL-17A y su uso en el tratamiento de trastornos autoinmunitarios e inflamatorios
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
AU2014223824B2
(en)
|
2013-02-28 |
2020-02-27 |
Albert Einstein College Of Medicine, Inc. |
Tuberculosis biomarkers and uses thereof
|
WO2014141064A1
(en)
|
2013-03-13 |
2014-09-18 |
Novartis Ag |
Notch2 binding molecules for treating respiratory diseases
|
EP2970479B1
(de)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antikörper gegen notch 3
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
GB201311031D0
(en)
*
|
2013-06-20 |
2013-08-07 |
Queen Mary & Westfield College |
Method
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
PE20160671A1
(es)
|
2013-08-02 |
2016-07-09 |
Pfizer |
Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
|
JP2016528247A
(ja)
|
2013-08-14 |
2016-09-15 |
ノバルティス アーゲー |
孤発性封入体筋炎を治療する方法
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
US10167322B2
(en)
|
2013-12-20 |
2019-01-01 |
Affibody Ab |
Engineered albumin binding polypeptide
|
EP3087101B1
(de)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulierbarer chimärer antigenrezeptor
|
US20170081411A1
(en)
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
KR20230164192A
(ko)
|
2014-05-06 |
2023-12-01 |
제넨테크, 인크. |
포유동물 세포를 사용한 이종다량체 단백질의 생산
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
JP6649358B2
(ja)
|
2014-08-07 |
2020-02-19 |
ノバルティス アーゲー |
アンジオポエチン様4抗体および使用法
|
TW201613977A
(en)
|
2014-08-07 |
2016-04-16 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
EP3194443B1
(de)
|
2014-09-17 |
2021-07-14 |
Novartis AG |
Targeting von zytotoxischen zellen mit chimären rezeptoren für eine adoptive immuntherapie
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
US20180320241A1
(en)
|
2014-12-19 |
2018-11-08 |
Roche Sequencing Solutions, Inc. |
Methods for identifying multiple epitopes in selected sub-populations of cells
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
WO2016105542A2
(en)
|
2014-12-24 |
2016-06-30 |
Neximmune, Inc |
Nanoparticle compositions and methods for immunotherapy
|
ES2901273T3
(es)
|
2015-04-06 |
2022-03-21 |
Subdomain Llc |
Polipéptidos que contienen dominios de unión de novo y usos de los mismos
|
EP3280729B1
(de)
|
2015-04-08 |
2022-04-27 |
Novartis AG |
Cd20-therapien, cd22-therapien und kombinationstherapien mit einer zelle zur expression des chimären antigen-rezeptors (car) cd19
|
BR112017021484A2
(pt)
|
2015-06-05 |
2018-07-03 |
Novartis Ag |
anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
JP2018528763A
(ja)
|
2015-07-31 |
2018-10-04 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
バイオフィルムの除去のためのペプチドおよび抗体
|
EP3331914A1
(de)
|
2015-08-03 |
2018-06-13 |
Novartis AG |
Verfahren zur behandlung von fgf21-vermittelten erkrankungen
|
UY36889A
(es)
|
2015-09-09 |
2017-04-28 |
Novartis Ag |
Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
|
EP3842457A1
(de)
|
2015-09-09 |
2021-06-30 |
Novartis AG |
Moleküle zur bindung von thymus-stroma-lymphopoietin (tslp) und verfahren zur verwendung der moleküle
|
WO2017066719A2
(en)
|
2015-10-14 |
2017-04-20 |
Research Institute At Nationwide Children's Hospital |
Hu specific interfering agents
|
EP3371311B1
(de)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bifunktionale chimäre proteine und verwendungen davon
|
WO2017087825A1
(en)
|
2015-11-19 |
2017-05-26 |
Asclepix Therapeutics, Llc. |
Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
|
EP3383920B1
(de)
|
2015-11-30 |
2024-01-10 |
The Regents of the University of California |
Freisetzung von tumorspezifischer nutzlast und immunaktivierung mit einem menschlichen antikörper gegen hochspezifisches tumorzellenoberflächenantigen
|
WO2017103895A1
(en)
|
2015-12-18 |
2017-06-22 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
WO2017121836A1
(en)
|
2016-01-15 |
2017-07-20 |
Thermo Fisher Scientific Baltics Uab |
Thermophilic dna polymerase mutants
|
US10988538B2
(en)
|
2016-02-05 |
2021-04-27 |
Orionis Biosciences BV |
Bispecific signaling agents and uses thereof
|
EP3426278B1
(de)
|
2016-03-07 |
2024-01-03 |
Vib Vzw |
Einzeldomänenantikörper gegen cd20
|
KR20170108203A
(ko)
|
2016-03-16 |
2017-09-27 |
주식회사 피플바이오 |
응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
|
EP3448887A1
(de)
|
2016-04-27 |
2019-03-06 |
Novartis AG |
Antikörper gegen den wachstumsdifferenzierungsfaktor 15 und verwendungen davon
|
CN110199019A
(zh)
|
2016-05-02 |
2019-09-03 |
Encodia有限公司 |
采用核酸编码的大分子分析
|
ES2874974T3
(es)
|
2016-05-11 |
2021-11-05 |
Cytiva Bioprocess R & D Ab |
Matriz de separación
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
US10889615B2
(en)
|
2016-05-11 |
2021-01-12 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
JP7106187B2
(ja)
|
2016-05-11 |
2022-07-26 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックスを保存する方法
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
ES2909833T3
(es)
|
2016-05-11 |
2022-05-10 |
Cytiva Bioprocess R & D Ab |
Método de limpieza y/o desinfección de una matriz de separación
|
CA3023883A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
US11753463B2
(en)
|
2016-05-13 |
2023-09-12 |
Orionis Biosciences BV |
Therapeutic targeting of non-cellular structures
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
CA3038809A1
(en)
|
2016-10-04 |
2018-04-12 |
Asclepix Therapeutics, Llc. |
Compounds and methods for activating tie2 signaling
|
JP7204643B2
(ja)
|
2016-10-24 |
2023-01-16 |
オリオニス バイオサイエンシズ ビーブイ |
標的変異インターフェロン-ガンマおよびその使用
|
EP3551766B1
(de)
|
2016-12-12 |
2022-09-14 |
Cepheid |
Integrierte immuno-pcr und nukleinsäureanalyse in einer automatisierten reaktionskartusche
|
BR112019012667A2
(pt)
|
2016-12-23 |
2020-02-11 |
Novartis Ag |
Anticorpos do fator xi e métodos de uso
|
WO2018129078A1
(en)
|
2017-01-04 |
2018-07-12 |
Research Institute At Nationwide Children's Hospital |
Dnabii vaccines and antibodies with enhanced activity
|
EP3576765A4
(de)
|
2017-02-06 |
2020-12-02 |
Orionis Biosciences, Inc. |
Zielgerichtetes manipuliertes interferon und verwendungen davon
|
JP7476467B2
(ja)
|
2017-02-06 |
2024-05-01 |
オリオンズ バイオサイエンス ビーブイ |
標的化キメラタンパク質及びその使用
|
EP3580230A1
(de)
|
2017-02-07 |
2019-12-18 |
VIB vzw |
Auf immunzellen gerichtete bispezifische chimäre proteine und verwendungen davon
|
WO2018146594A1
(en)
|
2017-02-08 |
2018-08-16 |
Novartis Ag |
Fgf21 mimetic antibodies and uses thereof
|
JP2020510432A
(ja)
|
2017-03-02 |
2020-04-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nectin−4への特異性を有する抗体及びその使用
|
AU2018236271B2
(en)
|
2017-03-15 |
2023-12-21 |
Research Institute At Nationwide Children's Hospital |
Composition and methods for disruption of bacterial biofilms without accompanying inflammation
|
EP3600415A1
(de)
|
2017-03-24 |
2020-02-05 |
Novartis AG |
Verfahren zur prävention und behandlung von herzerkrankungen
|
KR102014056B1
(ko)
|
2017-04-18 |
2019-08-27 |
앱클론(주) |
단백질의 순도 및 항원에 대한 친화성이 향상된 폴리펩티드, 이의 항체 또는 항원 결합 단편과의 복합체, 및 이들의 제조방법
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2019002178A1
(en)
|
2017-06-26 |
2019-01-03 |
Thermo Fisher Scientific Baltics Uab |
DNA MUTANTS THERMOPHILIC POLYMERASES
|
JP2020525421A
(ja)
|
2017-06-28 |
2020-08-27 |
ノバルティス アーゲー |
尿失禁を予防及び治療するための方法
|
US11674959B2
(en)
|
2017-08-03 |
2023-06-13 |
The Johns Hopkins University |
Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
KR102556494B1
(ko)
|
2017-10-31 |
2023-07-18 |
엔코디아, 인코포레이티드 |
핵산 암호화 및/또는 표지를 이용한 분석용 키트
|
CA3082410A1
(en)
|
2017-11-14 |
2019-05-23 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
WO2019099433A2
(en)
|
2017-11-14 |
2019-05-23 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
BR112020010016A2
(pt)
|
2017-11-22 |
2020-11-10 |
Novartis Ag |
agentes de ligação de reversão para anticorpos antifator xi/xia e usos dos mesmos
|
WO2019122200A1
(en)
|
2017-12-22 |
2019-06-27 |
Thermo Fisher Scientific Baltics Uab |
Polymerase chain reaction composition comprising amines
|
KR20200128533A
(ko)
|
2018-02-05 |
2020-11-13 |
오리오니스 바이오사이언시즈 인코포레이티드 |
섬유아세포 결합제 및 이의 용도
|
CN111989342A
(zh)
|
2018-04-18 |
2020-11-24 |
艾克隆株式会社 |
开关分子以及可转换嵌合抗原受体
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
DE202019005887U1
(de)
|
2018-07-03 |
2023-06-14 |
Marengo Therapeutics, Inc. |
Anti-TCR-Antikörpermoleküle und Verwendungen davon
|
EP3626265A1
(de)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human-cd45rc-antikörper und verwendungen davon
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
AU2019355194A1
(en)
|
2018-10-05 |
2021-04-22 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for enzymatic disruption of bacterial biofilms
|
AR117343A1
(es)
|
2018-12-18 |
2021-07-28 |
Novartis Ag |
AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
|
JP2022521723A
(ja)
|
2019-02-15 |
2022-04-12 |
インテグラル・モレキュラー・インコーポレイテッド |
クローディン6抗体及びその使用
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
JP2022524052A
(ja)
|
2019-03-08 |
2022-04-27 |
オックスフォード ジェネティクス リミテッド |
抗体の選択方法
|
GB201903233D0
(en)
|
2019-03-08 |
2019-04-24 |
Oxford Genetics Ltd |
Method of selecting for antibodies
|
WO2020198075A2
(en)
|
2019-03-22 |
2020-10-01 |
Reflexion Pharmaceuticals, Inc. |
Multivalent d-peptidic compounds for target proteins
|
CN114989298A
(zh)
|
2019-03-22 |
2022-09-02 |
反射制药有限公司 |
针对vegf的d-肽化合物
|
EP3963070A4
(de)
|
2019-04-30 |
2023-02-22 |
Encodia, Inc. |
Verfahren zur herstellung von analyten und zugehörige kits
|
EP3972997A1
(de)
|
2019-05-20 |
2022-03-30 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Neuartige anti-cd25-antikörper
|
KR20220030956A
(ko)
|
2019-07-05 |
2022-03-11 |
오노 야꾸힝 고교 가부시키가이샤 |
Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
|
JP2022540083A
(ja)
|
2019-07-08 |
2022-09-14 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
バイオフィルムを破壊するための抗体組成物
|
EP4011918A4
(de)
|
2019-08-08 |
2023-08-23 |
ONO Pharmaceutical Co., Ltd. |
Dual-spezifisches protein
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
CA3155930A1
(en)
|
2019-09-27 |
2021-04-01 |
Starkage Therapeutics |
SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THEM, AND USES THEREOF
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
AU2021237790A1
(en)
|
2020-03-20 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric antigen receptor specific for human CD45RC and uses thereof
|
GB202004514D0
(en)
|
2020-03-27 |
2020-05-13 |
Inst De Medicina Molecular Joaeo Lobo Antunes |
Treatment of Immunosuppressive Cancer
|
KR102502287B1
(ko)
|
2020-04-17 |
2023-02-22 |
앱클론(주) |
항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체
|
WO2021228956A1
(en)
|
2020-05-12 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
IL300528A
(en)
|
2020-08-07 |
2023-04-01 |
Fortis Therapeutics Inc |
Immune conjugates targeting cd46 and methods of using them
|
KR102350655B1
(ko)
|
2020-10-13 |
2022-01-12 |
인센 주식회사 |
테스토스테론-특이적 어피바디 및 이의 용도
|
EP4229068A1
(de)
|
2020-10-13 |
2023-08-23 |
Avitide LLC |
Affinitätsligandbibliotheken von drei helixbündelproteinen und verwendungen davon
|
EP4247496A1
(de)
|
2020-11-20 |
2023-09-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Anti-cd25-antikörper
|
CA3199006A1
(en)
|
2020-11-20 |
2022-05-27 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-cd25 antibodies
|
US20240108746A1
(en)
|
2020-12-16 |
2024-04-04 |
Molecular Partners Ag |
Novel slow-release prodrugs
|
EP4294542A1
(de)
|
2021-02-19 |
2023-12-27 |
Avitide LLC |
Aav2-affinitätswirkstoffe
|
CA3211368A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
JP2024508969A
(ja)
|
2021-03-09 |
2024-02-28 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
新規のDARPinに基づくCD33エンゲージャ
|
WO2022190008A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Protease cleavable prodrugs
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
WO2023170296A1
(en)
|
2022-03-11 |
2023-09-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Nucleic acid system to specifically reprogram b and t cells and uses thereof
|
WO2024003380A1
(en)
|
2022-06-30 |
2024-01-04 |
Icm (Institut Du Cerveau Et De La Moelle Épinière) |
Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024077118A2
(en)
|
2022-10-06 |
2024-04-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|